Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02561234 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Aeglea Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT02561234: Completed Phase 1 study, sponsored by Aeglea Biotherapeutics.
NCT02561234 is a Phase 1 study that has completed, run by Aeglea Biotherapeutics. The registered enrollment target is 98 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02561234, a Phase 1 study, has completed, sponsored by Aeglea Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This is the first-in-human study of the safety of increasing dose levels of AEB1102 in patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and tumor growth.
Primary Outcome
the dose level at which no more than 1/6 patients experiences dose-limiting toxicity
Interventions
- DRUG Co-ArgI-PEG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-05 |
| Phase | Phase 1 |
What the finished NCT02561234 record still lists
NCT02561234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 1 intervention - of which Co-ArgI-PEG is the first listed.
NCT02561234 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02561234 about?
NCT02561234 is a clinical study titled "A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors". This is the first-in-human study of the safety of increasing dose levels of AEB1102 in patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and tumor growth.
What is the current status of trial NCT02561234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2015-10. Estimated completion is 2019-05.
What interventions are being tested in trial NCT02561234?
The interventions under investigation include: Co-ArgI-PEG (DRUG).
Who is sponsoring clinical trial NCT02561234?
This trial is sponsored by Aeglea Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02561234's enrollment target sits among peer trials
98 592nd of 2000 higher than 1,404 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia